Search
Now showing items 1-10 of 13
Syntheses of sulfanylphthalimide and xanthine analogues and their evaluation as inhibitors of monoamine oxidase and as antagonists of adenosine receptors
(North-West University, 2013)
Currently L-DOPA is the drug most commonly used for the treatment of Parkinson’s disease (PD). However, the long-term use of L-DOPA is associated with the development of motor fluctuations and dyskinesias. Treatment mainly ...
Monoamine oxidase inhibitory activities of heterocyclic chalcones
(2013)
Parkinson’s disease is the second most common age-related neurodegenerative disease after Alzheimer’s disease. The characteristic pathological feature of Parkinson’s disease is the loss of neurons in the substantia nigra ...
Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase
(2014)
BACKGROUND AND RATIONALE
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder affecting the central nervous system, primarily, the substantia nigra. It is characterized by loss of dopaminergic ...
Monoamine oxidase inhibition by indanone and benzoquinone analogues
(North-West University (South Africa) , Potchefstroom Campus, 2015)
Parkinson’s disease (PD) is a neurological disorder of which aging is the greatest risk factor. Over the next fifteen years, the number of persons affected by PD worldwide is expected to increase from 4.6 million to 9.3 ...
Synthesis and biological evaluation of 6-substituted coumaranone derivatives and related compounds as monoamine oxidase inhibitors
(2014)
Parkinson’s disease (PD) is an age related neurodegenerative disorder that presents with both motor and non-motor symptoms. The most common pathological characteristic of PD is the loss of the pigmented dopaminergic neurons ...
In silico screening, synthesis and in vitro determination of the biological activities of D-amino acid oxidase inhibitors
(North-West University (South-Africa), 2022)
Schizophrenia is a mental disorder with many clinical and therapeutic challenges. Current therapy is based on outdated pathological theories while most antipschycotic drugs have a significant side effect profile. New ...
Evaluation of selected dye compounds as inhibitors of monoamine oxidase
(North-West University (South-Africa), 2019)
Parkinson’s disease (PD) and Alzheimer’s disease (AD) are neurodegenerative diseases that significantly impact the quality of life of patients. The pathology of Parkinson’s disease is characterised by neuronal death of the ...
Evaluation of selected dye compounds as inhibitors of enzymes, relevant to neurological disorders
(North-West University (South-Africa), 2021)
Neurological disorders such as Alzheimer’s disease, Parkinson’s disease and schizophrenia are disorders that affect a large part of the population, especially the elderly. The cause of these disorders is still not completely ...
Synthesis and evaluation of sesamol derivatives as inhibitors of monoamine oxidase
(2014)
Parkinson’s disease is an age-related neurodegenerative disorder. The major symptoms of Parkinson’s disease are closely linked to the pathology of the disease. The main pathology of Parkinson’s disease consists of the ...
Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase
(2015)
Parkinson’s disease is a bradykinetic disorder that is the result of the death of dopaminergic neurons in the basal ganglia of the brain. This, in turn, leads to the depletion of dopamine in the striatum, which is responsible ...